Puerto Rico Tax-Haven Status, R&D Credit Weakened By Tax-Reform Bill
Executive Summary
Under tax reform legislation recently passed by Congress, a 20% tax on products made in domestic territories will adversely affect the many device firms with Puerto Rican plants that currently enjoy a lower, 4% tax rate on profits. And a second tax provision usually relied upon by medtech companies, the R&D tax credit, also loses ground under the final Senate bill passed Dec. 2.
You may also be interested in...
'Big Shoes To Fill' As Hatch Retirement Leaves Supplement Market Legacy
Sen. Orrin Hatch won’t seek re-election and will leave 24 years after Congress passed the Dietary Supplement Health and Education Act as a framework for FDA's regulation of vitamin, mineral and supplement product manufacturing and marketing. Hatch is in his seventh term and is the longest-serving Senate member.
Conferees Kill Corporate AMT In Tax Bill, Freeing Use Of R&D Credits
Members of a tax reform bill conference committee repealed a controversial corporate alternative minimum tax, which will allow more device firms to take advantage of research & development tax credits. That was one of several changes made to help win the tax bill's final passage, anticipated this week.
Medtech To Benefit From 20% Corporate Rate, Tax-Free Foreign Transfers In Pending US Tax Bill
Medical device firms will benefit from a Republican tax bill that has passed the full US House and a key Senate committee. The bill lowers the corporate tax rate to 20% from a maximum of 35%, treats foreign-earned intangible income at a favorably low rate of 12.5%, and permits tax-free transfers of intangible corporate property, such as patents, from foreign firms to US parents.